EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Gene therapy for adenosine deaminase severe combined immune deficiency—An unexpected journey of four decades

Donald B Kohn iD

Immunological Reviews · 2024

DOI: 10.1111/imr.13293 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunological Reviews, 2024. Verfasst von Donald B Kohn. Beteiligte Einrichtung: Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, Cal…. Hauptthemen laut MEDLINE: Severe Combined Immunodeficiency, Hematopoietic Stem Cell Transplantation, Agammaglobulinemia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: NIAID NIH HHS, UCLA Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research endowment.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe combined immune deficiency due to adenosine deaminase deficiency (ADA SCID) is an inborn error of immunity with pan‐lymphopenia, due to accumulated cytotoxic adenine metabolites. ADA SCID has been treated using gene therapy with a normal human ADA gene added to autologous hematopoietic stem cells (HSC) for over 30 years. Iterative improvements in vector design, HSC processing methods, and clinical HSC transplant procedures have led nearly all ADA SCID gene therapy patients to achieve consistently beneficial immune restoration with stable engraftment of ADA gene‐corrected HSC over the duration of observation (as long as 20 years). One gene therapy for ADA SCID is approved by the European Medicines Agency (EMA) in the European Union (EU) and another is being advanced to licensure in the U.S. and U.K. Despite the clear‐cut benefits and safety of this curative gene and cell therapy, it remains challenging to achieve sustained availability and access, especially for rare disorders like ADA SCID.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Severe Combined ImmunodeficiencyHematopoietic Stem Cell TransplantationAgammaglobulinemiaHumansAdenosine DeaminaseGenetic Therapy

Stichwörter der Autor:innen

adenosine deaminase severe combined immune deficiency (ADA SCID)autologous hematopoietic stem cell transplantationclinical trialsgene therapyinborn errors of immunityorphan diseasesviral vectors

Substanzen

Adenosine Deaminase

Autor:innen und Institutionen

  • Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
  • Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
  • Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

ORCID-Profile: Donald B Kohn

Förderung

  • NIAID NIH HHS
  • UCLA Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research endowment

Zitieren

APA

Kohn, D. B. (2024). Gene therapy for adenosine deaminase severe combined immune deficiency—An unexpected journey of four decades. Immunological Reviews. https://doi.org/10.1111/imr.13293

Vancouver

Kohn DB. Gene therapy for adenosine deaminase severe combined immune deficiency—An unexpected journey of four decades. Immunological Reviews. 2024. doi:10.1111/imr.13293

BibTeX
@article{Kohn2024,
  author = {Kohn, Donald B},
  title = {Gene therapy for adenosine deaminase severe combined immune deficiency—An unexpected journey of four decades},
  journal = {Immunological Reviews},
  year = {2024},
  doi = {10.1111/imr.13293}
}
Kostenlos starten →